Several brokerages have updated their recommendations and price targets on shares of EXACT Sciences (NASDAQ: EXAS) in the last few weeks:

  • 3/8/2018 – EXACT Sciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 3/1/2018 – EXACT Sciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/28/2018 – EXACT Sciences was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “
  • 2/27/2018 – EXACT Sciences was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $56.00 price target on the stock, up previously from $42.56.
  • 2/23/2018 – EXACT Sciences was downgraded by analysts at Benchmark Co. from a “buy” rating to a “hold” rating.
  • 2/23/2018 – EXACT Sciences was given a new $67.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 2/23/2018 – EXACT Sciences was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 2/9/2018 – EXACT Sciences was given a new $67.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 2/7/2018 – EXACT Sciences was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/29/2018 – EXACT Sciences is now covered by analysts at Goldman Sachs Group Inc. They set a “neutral” rating and a $51.00 price target on the stock.
  • 1/19/2018 – EXACT Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “
  • 1/17/2018 – EXACT Sciences was given a new $65.00 price target on by analysts at Benchmark Co.. They now have a “buy” rating on the stock.
  • 1/16/2018 – EXACT Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $62.00 price target on the stock. According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “

EXACT Sciences Co. (NASDAQ EXAS) opened at $52.55 on Wednesday. The company has a market capitalization of $6,290.00, a P/E ratio of -25.76 and a beta of 0.71. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 1-year low of $19.91 and a 1-year high of $63.60.

How to Become a New Pot Stock Millionaire

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Thursday, February 22nd. The medical research company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative return on equity of 24.13% and a negative net margin of 43.01%. The business had revenue of $87.41 million for the quarter, compared to the consensus estimate of $87.42 million. During the same period in the previous year, the business earned ($0.34) EPS. EXACT Sciences’s revenue was up 148.0% compared to the same quarter last year. research analysts anticipate that EXACT Sciences Co. will post -0.84 earnings per share for the current fiscal year.

In other EXACT Sciences news, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total transaction of $87,479.10. Following the transaction, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kevin T. Conroy sold 123,512 shares of the company’s stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $52.58, for a total value of $6,494,260.96. Following the transaction, the insider now directly owns 953,564 shares in the company, valued at approximately $50,138,395.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 573,050 shares of company stock worth $28,372,929. Company insiders own 4.00% of the company’s stock.

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Receive News & Ratings for EXACT Sciences Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co and related companies with MarketBeat.com's FREE daily email newsletter.